Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$7.22M |
$0.61
-2.78%
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$7.00M |
$2.02
-1.23%
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$6.98M |
$4.26
-6.67%
|
|
XAIR
Beyond Air, Inc.
UNO program for solid tumors places Beyond Air in oncology-focused biotech pipelines.
|
$6.94M |
$0.85
-1.96%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$6.94M |
$0.98
+2.24%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$6.94M |
$0.44
-1.77%
|
|
ACUT
Accustem Sciences Inc.
Tests and technologies are oncology-focused biomarker diagnostics, placing ACUT in the oncology diagnostics space.
|
$6.93M |
$0.43
|
|
ICU
SeaStar Medical Holding Corporation
QUELIMMUNE represents an immunology therapeutic, aligning with Immunology Therapeutics.
|
$6.64M |
$2.36
-0.84%
|
|
KTTA
Pasithea Therapeutics Corp.
Pasithea's lead candidate PAS-4.00 is a MEK inhibitor targeting MAPK pathway-driven tumors, aligning with oncology-focused biotech.
|
$6.56M |
$0.85
+1.50%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$6.53M |
$1.14
+6.07%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$6.45M |
$0.28
-3.65%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$6.43M |
$0.25
+1.38%
|
|
DQWS
DSwiss, Inc.
DQWS provides turnkey OEM/ODM contract manufacturing services for health care, beauty, and nutraceutical products.
|
$6.41M |
$0.03
|
|
ALZN
Alzamend Neuro, Inc.
Company's pipeline includes Alzheimer's disease therapeutics (ALZN002) and a focused strategy on Alzheimer's treatment.
|
$6.22M |
$1.98
-0.25%
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$6.15M |
$0.62
+2.46%
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$6.14M |
$1.07
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$6.03M |
$5.04
+0.80%
|
|
ALUR
Allurion Technologies Inc.
Drug delivery platform angle via GLP-1 drug-eluting intragastric balloon; joint development.
|
$5.89M |
$0.79
+4.11%
|
|
BMRA
Biomerica, Inc.
Offers Contract Manufacturing services with notable growth, i.e., contract manufacturing revenue stream.
|
$5.83M |
$2.02
-0.74%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$5.64M |
$3.01
+7.50%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$5.60M |
N/A
|
|
SBFM
Sunshine Biopharma, Inc.
SBFM's Nora Pharma operates a growing Canadian generic prescription drug business.
|
$5.47M |
$1.17
-4.88%
|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$5.34M |
$0.90
+2.67%
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.07M |
$1.55
-0.26%
|
|
IBO
Impact BioMedical Inc.
Linebacker is an oncology-focused platform of electrophilically enhanced polyphenol compounds licensed for development and commercialization.
|
$5.04M |
$0.65
+57.54%
|
|
SNGX
Soligenix, Inc.
HyBryte CTCL and related oncology assets position Soligenix in Biotech - Oncology.
|
$5.01M |
$1.17
-0.43%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$4.80M |
$1.85
-0.54%
|
|
SNOA
Sonoma Pharmaceuticals, Inc.
Eye care products, aligning with ophthalmic drug offerings.
|
$4.76M |
$2.65
-5.36%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB's encapsulation technology is a drug-delivery platform enabling localized prodrug activation.
|
$4.71M |
$0.70
+0.53%
|
|
BGLC
BioNexus Gene Lab Corp.
Chemrex pivot to biotech-focused CDMO activities positions it as a Contract Manufacturing Organization.
|
$4.71M |
$2.57
-1.91%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$4.63M |
$0.80
-3.27%
|
|
IMRN
Immuron Limited
Core polyclonal antibody technology platform powering gut-health products and clinical programs in immunology/biotherapeutics.
|
$4.36M |
$0.80
+7.07%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$4.36M |
$3.21
+3.22%
|
|
POAI
Predictive Oncology Inc.
Biotech - Oncology focus via proprietary biobank, wet-lab validation, and AI-enabled oncology drug discovery.
|
$4.32M |
$5.94
-0.17%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
ALS is a rare neurodegenerative disease, aligning with the Rare Diseases biotech segment and supporting NurOwn's positioning as a therapy for a rare condition.
|
$4.24M |
$0.70
|
Showing page 23 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
